172348-63-9

Basic information

• Product Name: trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97%
• Synonyms: trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97%;Carbamic acid, N-[[trans-4-(hydroxymethyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester;TRANS-4-BOC-AMINOMETHYL-1-HYDROXYMETHYL-CYCLOHEXANE
• CAS NO: 172348-63-9
• Molecular Formula: C₁₃H₂₅NO₃
• Molecular Weight: 243.3425
• Mol File: 172348-63-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 367.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.009±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12.81±0.46(Predicted)
• CAS DataBase Reference: trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97%(172348-63-9)
• EPA Substance Registry System: trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97%(172348-63-9)

Safety Data

• Hazardous Substances Data: 172348-63-9(Hazardous Substances Data)

Usage

General Description

Trans-4-(Boc-aminoMethyl)cyclohexaneMethanol, 97% is a chemical compound that is commonly used in organic synthesis. It is a white solid with a purity of 97%, and its molecular formula is C14H25NO4. The compound contains a Boc (tert-butoxycarbonyl) protective group, which is often used to protect amines during chemical reactions. The presence of a cyclohexane ring in the molecule makes it useful for the preparation of various organic compounds, and the hydroxyl group allows for potential modification and functionalization. This chemical is commonly used in the pharmaceutical and chemical industries for the synthesis of various drugs and organic compounds.

Upstream product

• 27687-14-5 trans 4-(tert-butyloxycarbonylamino)methylcyclohexanecarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 178972-33-3 trans-4-(aminomethyl)cyclohexanemethanol hydrochloride 

Downstream Products

• 178972-34-4 toluene-4-sulfonic acid 4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl ester 
• 1187857-60-8 ethyl 2-(((1r,4r)-4-((tert-butoxycarbonylamino)methyl)cyclohexyl)methoxy)acetate 
• 1187857-15-3 tert-butyl 2-(((1r,4r)-4-((tert-butoxycarbonylamino)methyl)cyclohexyl)methoxy)acetate 
• 1187857-57-3 2-(((1r,4r)-4-((3-(2-fluoro-3-methoxyphenyl)-3-phenylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-28-8 2-(((1r,4r)-4-((3-(3-chlorophenyl)-3-phenylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-17-5 2-(((1r,4r)-4-((3-(3-methoxyphenyl)-3-phenylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187856-37-6 2-(((1r,4r)-4-((3-benzhydryl-3-methylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-16-4 2-(((1r,4r)-4-((3-benzhydrylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-14-2 2-(((1r,4r)-4-((3,3-diphenylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-61-9 ethyl 2-(((1r,4r)-4-(aminomethyl)cyclohexyl)methoxy)acetate 

Relevant articles and documents

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator

In this letter we report the synthesis and biochemical evaluation of selective, irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator (uPA). A diphenyl phosphonate group was introduced on the substratelike peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated. A guanylated benzyl group appeared the most promising side chain modification. A kapp value in the 103 M -1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.

Compositions and methods for treating mast-cell mediated conditions

Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.